APO Research
Talk to an analyst

APO RESEARCH · REPORT

EGFR-TKI

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global EGFR-TKI Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

27 December 2025199 pages

Choose your research edition.

Industry ResearchEGFR-TKI Industry Research Report 2026133 pages · $2,950 USDIndustry Growth & TrendsGlobal EGFR-TKI Industry Growth and Trends Forecast to 2032118 pages · $3,450 USDMarket StructureGlobal EGFR-TKI Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal EGFR-TKI Market Outlook and Growth Opportunities 2026206 pages · $4,250 USDMarket Analysis & ForecastGlobal EGFR-TKI Market Analysis and Forecast 2026-2032200 pages · $4,950 USD

Market perspective

The global EGFR-TKI market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for EGFR-TKI is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for EGFR-TKI is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for EGFR-TKI is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for EGFR-TKI is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of EGFR-TKI include ArriVent Biopharma, AstraZeneca, Beacon Pharma, Boehringer Ingelheim Pharmaceuticals, Cipla, Drug International, Glenmark Pharmaceuticals, Hanmi Pharmaceutical and Johnson & Johnson, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global EGFR-TKI market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of EGFR-TKI and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents EGFR-TKI sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the EGFR-TKI market size, projected growth trends, production technologies, key applications, and end-use industries.

EGFR-TKI Segment by Company

ArriVent Biopharma

AstraZeneca

Beacon Pharma

Boehringer Ingelheim Pharmaceuticals

Cipla

Drug International

Glenmark Pharmaceuticals

Hanmi Pharmaceutical

Johnson & Johnson

Mylan

Pfizer

Roche

Teva

Yuhan Corporation

Betta Pharma

Chengdu Brilliant Pharmaceuticals

Hansoh Pharma

Shanghai Allist Pharmaceuticals

Wanbang Biopharmaceuticals

EGFR-TKI Segment by Type

Afatinib

Aumolertinib

Icotinib

Osimertinib

Dacomitinib

Erlotinib

Furmonertinib

Gefitinib

Lazertinib

Other

EGFR-TKI Segment by Application

Segment by Application

Hospital and Clinic

Retail Pharmacies

Other

EGFR-TKI Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global EGFR-TKI market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of EGFR-TKI and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of EGFR-TKI.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the EGFR-TKI market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of EGFR-TKI manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of EGFR-TKI in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of EGFR-TKI in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. EGFR-TKI Industry Trends Table 2. EGFR-TKI Industry Drivers Table 3. EGFR-TKI Industry Opportunities and Challenges Table 4. EGFR-TKI Industry Restraints Table 5. Global EGFR-TKI Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global EGFR-TKI Revenue Market Share by Manufacturers (2021-2026) Table 7. Global EGFR-TKI Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global EGFR-TKI Sales Market Share by Manufacturers Table 9. Global EGFR-TKI Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global EGFR-TKI Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global EGFR-TKI Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global EGFR-TKI Manufacturers, Product Type & Application Table 13. Global EGFR-TKI Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global EGFR-TKI by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Afatinib Table 17. Major Manufacturers of Aumolertinib Table 18. Major Manufacturers of Icotinib Table 19. Major Manufacturers of Osimertinib Table 20. Major Manufacturers of Dacomitinib Table 21. Major Manufacturers of Erlotinib Table 22. Major Manufacturers of Furmonertinib Table 23. Major Manufacturers of Gefitinib Table 24. Major Manufacturers of Lazertinib Table 25. Major Manufacturers of Other Table 26. Global EGFR-TKI Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 27. Global EGFR-TKI Sales by Type (2021-2026) & (K Units) Table 28. Global EGFR-TKI Sales by Type (2027-2032) & (K Units) Table 29. Global EGFR-TKI Sales Market Share by Type (2021-2026) Table 30. Global EGFR-TKI Sales Market Share by Type (2027-2032) Table 31. Global EGFR-TKI Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 32. Global EGFR-TKI Revenue by Type (2021-2026) & (K Units) Table 33. Global EGFR-TKI Revenue by Type (2027-2032) & (K Units) Table 34. Global EGFR-TKI Revenue Market Share by Type (2021-2026) Table 35. Global EGFR-TKI Revenue Market Share by Type (2027-2032) Table 36. Major Manufacturers of Segment by Application Table 37. Major Manufacturers of Hospital and Clinic Table 38. Major Manufacturers of Retail Pharmacies Table 39. Major Manufacturers of Other Table 40. Global EGFR-TKI Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 41. Global EGFR-TKI Sales by Application (2021-2026) & (K Units) Table 42. Global EGFR-TKI Sales by Application (2027-2032) & (K Units) Table 43. Global EGFR-TKI Sales Market Share by Application (2021-2026) Table 44. Global EGFR-TKI Sales Market Share by Application (2027-2032) Table 45. Global EGFR-TKI Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 46. Global EGFR-TKI Revenue by Application (2021-2026) & (K Units) Table 47. Global EGFR-TKI Revenue by Application (2027-2032) & (K Units) Table 48. Global EGFR-TKI Revenue Market Share by Application (2021-2026) Table 49. Global EGFR-TKI Revenue Market Share by Application (2027-2032) Table 50. Global EGFR-TKI Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 51. Global EGFR-TKI Sales by Region (2021-2026) & (K Units) Table 52. Global EGFR-TKI Sales Market Share by Region (2021-2026) Table 53. Global EGFR-TKI Sales Forecasted by Region (2027-2032) & (K Units) Table 54. Global EGFR-TKI Sales Forecasted Market Share by Region (2027-2032) Table 55. North America EGFR-TKI Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. North America EGFR-TKI Sales by Country (2021-2026) & (K Units) Table 57. North America EGFR-TKI Sales by Country (2027-2032) & (K Units) Table 58. Europe EGFR-TKI Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 59. Europe EGFR-TKI Sales by Country (2021-2026) & (K Units) Table 60. Europe EGFR-TKI Sales by Country (2027-2032) & (K Units) Table 61. Asia Pacific EGFR-TKI Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 62. Asia Pacific EGFR-TKI Sales by Country (2021-2026) & (K Units) Table 63. Asia Pacific EGFR-TKI Sales by Country (2027-2032) & (K Units) Table 64. South America, Middle East and Africa EGFR-TKI Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 65. South America, Middle East and Africa EGFR-TKI Sales by Country (2021-2026) & (K Units) Table 66. South America, Middle East and Africa EGFR-TKI Sales by Country (2027-2032) & (K Units) Table 67. Global EGFR-TKI Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 68. Global EGFR-TKI Revenue by Region (2021-2026) & (US$ Million) Table 69. Global EGFR-TKI Revenue by Region (2027-2032) & (US$ Million) Table 70. Global EGFR-TKI Revenue Market Share by Region (2021-2026) Table 71. Global EGFR-TKI Revenue Market Share by Region (2027-2032) Table 72. ArriVent Biopharma Company Information Table 73. ArriVent Biopharma Business Overview Table 74. ArriVent Biopharma EGFR-TKI Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. ArriVent Biopharma EGFR-TKI Product Portfolio Table 76. ArriVent Biopharma Recent Development Table 77. AstraZeneca Company Information Table 78. AstraZeneca Business Overview Table 79. AstraZeneca EGFR-TKI Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. AstraZeneca EGFR-TKI Product Portfolio Table 81. AstraZeneca Recent Development Table 82. Beacon Pharma Company Information Table 83. Beacon Pharma Business Overview Table 84. Beacon Pharma EGFR-TKI Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Beacon Pharma EGFR-TKI Product Portfolio Table 86. Beacon Pharma Recent Development Table 87. Boehringer Ingelheim Pharmaceuticals Company Information Table 88. Boehringer Ingelheim Pharmaceuticals Business Overview Table 89. Boehringer Ingelheim Pharmaceuticals EGFR-TKI Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Boehringer Ingelheim Pharmaceuticals EGFR-TKI Product Portfolio Table 91. Boehringer Ingelheim Pharmaceuticals Recent Development Table 92. Cipla Company Information Table 93. Cipla Business Overview Table 94. Cipla EGFR-TKI Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 95. Cipla EGFR-TKI Product Portfolio Table 96. Cipla Recent Development Table 97. Drug International Company Information Table 98. Drug International Business Overview Table 99. Drug International EGFR-TKI Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 100. Drug International EGFR-TKI Product Portfolio Table 101. Drug International Recent Development Table 102. Glenmark Pharmaceuticals Company Information Table 103. Glenmark Pharmaceuticals Business Overview Table 104. Glenmark Pharmaceuticals EGFR-TKI Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 105. Glenmark Pharmaceuticals EGFR-TKI Product Portfolio Table 106. Glenmark Pharmaceuticals Recent Development Table 107. Hanmi Pharmaceutical Company Information Table 108. Hanmi Pharmaceutical Business Overview Table 109. Hanmi Pharmaceutical EGFR-TKI Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 110. Hanmi Pharmaceutical EGFR-TKI Product Portfolio Table 111. Hanmi Pharmaceutical Recent Development Table 112. Johnson & Johnson Company Information Table 113. Johnson & Johnson Business Overview Table 114. Johnson & Johnson EGFR-TKI Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 115. Johnson & Johnson EGFR-TKI Product Portfolio Table 116. Johnson & Johnson Recent Development Table 117. Mylan Company Information Table 118. Mylan Business Overview Table 119. Mylan EGFR-TKI Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 120. Mylan EGFR-TKI Product Portfolio Table 121. Mylan Recent Development Table 122. Pfizer Company Information Table 123. Pfizer Business Overview Table 124. Pfizer EGFR-TKI Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 125. Pfizer EGFR-TKI Product Portfolio Table 126. Pfizer Recent Development Table 127. Roche Company Information Table 128. Roche Business Overview Table 129. Roche EGFR-TKI Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 130. Roche EGFR-TKI Product Portfolio Table 131. Roche Recent Development Table 132. Teva Company Information Table 133. Teva Business Overview Table 134. Teva EGFR-TKI Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 135. Teva EGFR-TKI Product Portfolio Table 136. Teva Recent Development Table 137. Yuhan Corporation Company Information Table 138. Yuhan Corporation Business Overview Table 139. Yuhan Corporation EGFR-TKI Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 140. Yuhan Corporation EGFR-TKI Product Portfolio Table 141. Yuhan Corporation Recent Development Table 142. Betta Pharma Company Information Table 143. Betta Pharma Business Overview Table 144. Betta Pharma EGFR-TKI Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 145. Betta Pharma EGFR-TKI Product Portfolio Table 146. Betta Pharma Recent Development Table 147. Chengdu Brilliant Pharmaceuticals Company Information Table 148. Chengdu Brilliant Pharmaceuticals Business Overview Table 149. Chengdu Brilliant Pharmaceuticals EGFR-TKI Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 150. Chengdu Brilliant Pharmaceuticals EGFR-TKI Product Portfolio Table 151. Chengdu Brilliant Pharmaceuticals Recent Development Table 152. Hansoh Pharma Company Information Table 153. Hansoh Pharma Business Overview Table 154. Hansoh Pharma EGFR-TKI Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 155. Hansoh Pharma EGFR-TKI Product Portfolio Table 156. Hansoh Pharma Recent Development Table 157. Shanghai Allist Pharmaceuticals Company Information Table 158. Shanghai Allist Pharmaceuticals Business Overview Table 159. Shanghai Allist Pharmaceuticals EGFR-TKI Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 160. Shanghai Allist Pharmaceuticals EGFR-TKI Product Portfolio Table 161. Shanghai Allist Pharmaceuticals Recent Development Table 162. Wanbang Biopharmaceuticals Company Information Table 163. Wanbang Biopharmaceuticals Business Overview Table 164. Wanbang Biopharmaceuticals EGFR-TKI Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 165. Wanbang Biopharmaceuticals EGFR-TKI Product Portfolio Table 166. Wanbang Biopharmaceuticals Recent Development Table 167. Key Raw Materials Table 168. Raw Materials Key Suppliers Table 169. EGFR-TKI Distributors List Table 170. EGFR-TKI Customers List Table 171. Research Programs/Design for This Report Table 172. Authors List of This Report Table 173. Secondary Sources Table 174. Primary Sources List of Figures Figure 1. EGFR-TKI Product Image Figure 2. Global EGFR-TKI Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global EGFR-TKI Market Size (2021-2032) & (US$ Million) Figure 4. Global EGFR-TKI Sales (2021-2032) & (K Units) Figure 5. Global EGFR-TKI Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 EGFR-TKI Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Afatinib Image Figure 9. Aumolertinib Image Figure 10. Icotinib Image Figure 11. Osimertinib Image Figure 12. Dacomitinib Image Figure 13. Erlotinib Image Figure 14. Furmonertinib Image Figure 15. Gefitinib Image Figure 16. Lazertinib Image Figure 17. Other Image Figure 18. Global EGFR-TKI Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 19. Global EGFR-TKI Sales Market Share 2021 VS 2025 VS 2032 Figure 20. Global EGFR-TKI Sales Market Share by Type (2021-2032) Figure 21. Global EGFR-TKI Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global EGFR-TKI Revenue Market Share 2021 VS 2025 VS 2032 Figure 23. Global EGFR-TKI Revenue Market Share by Type (2021-2032) Figure 24. Segment by Application Image Figure 25. Hospital and Clinic Image Figure 26. Retail Pharmacies Image Figure 27. Other Image Figure 28. Global EGFR-TKI Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 29. Global EGFR-TKI Sales Market Share 2021 VS 2025 VS 2032 Figure 30. Global EGFR-TKI Sales Market Share by Application (2021-2032) Figure 31. Global EGFR-TKI Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 32. Global EGFR-TKI Revenue Market Share 2021 VS 2025 VS 2032 Figure 33. Global EGFR-TKI Revenue Market Share by Application (2021-2032) Figure 34. North America EGFR-TKI Sales and Growth Rate (2021-2032) & (K Units) Figure 35. North America EGFR-TKI Sales Market Share by Country (2021-2032) Figure 36. U.S. EGFR-TKI Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Canada EGFR-TKI Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Mexico EGFR-TKI Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Europe EGFR-TKI Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Europe EGFR-TKI Sales Market Share by Country (2021-2032) Figure 41. Germany EGFR-TKI Sales and Growth Rate (2021-2032) & (K Units) Figure 42. France EGFR-TKI Sales and Growth Rate (2021-2032) & (K Units) Figure 43. U.K. EGFR-TKI Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Italy EGFR-TKI Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Netherlands EGFR-TKI Sales and Growth Rate (2021-2032) & (K Units) Figure 46. Asia Pacific EGFR-TKI Sales and Growth Rate (2021-2032) & (K Units) Figure 47. Asia Pacific EGFR-TKI Sales Market Share by Country (2021-2032) Figure 48. China EGFR-TKI Sales and Growth Rate (2021-2032) & (K Units) Figure 49. Japan EGFR-TKI Sales and Growth Rate (2021-2032) & (K Units) Figure 50. South Korea EGFR-TKI Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Southeast Asia EGFR-TKI Sales and Growth Rate (2021-2032) & (K Units) Figure 52. India EGFR-TKI Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Australia EGFR-TKI Sales and Growth Rate (2021-2032) & (K Units) Figure 54. South America, Middle East and Africa EGFR-TKI Sales and Growth Rate (2021-2032) & (K Units) Figure 55. South America, Middle East and Africa EGFR-TKI Sales Market Share by Country (2021-2032) Figure 56. Brazil EGFR-TKI Sales and Growth Rate (2021-2032) & (K Units) Figure 57. South Africa EGFR-TKI Sales and Growth Rate (2021-2032) & (K Units) Figure 58. Saudi Arabia EGFR-TKI Sales and Growth Rate (2021-2032) & (K Units) Figure 59. Turkey EGFR-TKI Sales and Growth Rate (2021-2032) & (K Units) Figure 60. Argentina EGFR-TKI Sales and Growth Rate (2021-2032) & (K Units) Figure 61. UAE EGFR-TKI Sales and Growth Rate (2021-2032) & (K Units) Figure 62. Egypt EGFR-TKI Sales and Growth Rate (2021-2032) & (K Units) Figure 63. Chile EGFR-TKI Sales and Growth Rate (2021-2032) & (K Units) Figure 64. Global EGFR-TKI Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 65. Global EGFR-TKI Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 66. North America EGFR-TKI Revenue (2021-2032) & (US$ Million) Figure 67. North America EGFR-TKI Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. Europe EGFR-TKI Revenue (2021-2032) & (US$ Million) Figure 69. Europe EGFR-TKI Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 70. Asia-Pacific EGFR-TKI Revenue (2021-2032) & (US$ Million) Figure 71. Asia-Pacific EGFR-TKI Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 72. South America, Middle East and Africa EGFR-TKI Revenue (2021-2032) & (US$ Million) Figure 73. South America, Middle East and Africa EGFR-TKI Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 74. EGFR-TKI Value Chain Figure 75. Manufacturing Cost Structure Figure 76. EGFR-TKI Production Mode & Process Figure 77. Direct Comparison with Distribution Share Figure 78. Distributors Profiles Figure 79. Years Considered Figure 80. Research Process Figure 81. Key Executives Interviewed

Scope & coverage.

Types
  • Afatinib
  • Aumolertinib
  • Icotinib
  • Osimertinib
  • Dacomitinib
  • Erlotinib
  • Furmonertinib
  • Gefitinib
  • Lazertinib
  • Other
Applications
  • Segment by Application
  • Hospital and Clinic
  • Retail Pharmacies
  • Other
Companies covered
  • ArriVent Biopharma
  • AstraZeneca
  • Beacon Pharma
  • Boehringer Ingelheim Pharmaceuticals
  • Cipla
  • Drug International
  • Glenmark Pharmaceuticals
  • Hanmi Pharmaceutical
  • Johnson & Johnson
  • Mylan
  • Pfizer
  • Roche
  • Teva
  • Yuhan Corporation
  • Betta Pharma
  • Chengdu Brilliant Pharmaceuticals
  • Hansoh Pharma
  • Shanghai Allist Pharmaceuticals
  • Wanbang Biopharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global EGFR-TKI Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global EGFR-TKI Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global EGFR-TKI Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global EGFR-TKI Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global EGFR-TKI Market Dynamics
  1. 2.1 EGFR-TKI Industry Trends
  2. 2.2 EGFR-TKI Industry Drivers
  3. 2.3 EGFR-TKI Industry Opportunities and Challenges
  4. 2.4 EGFR-TKI Industry Restraints
3 EGFR-TKI Market by Manufacturers
  1. 3.1 Global EGFR-TKI Revenue by Manufacturers (2021-2026)
  2. 3.2 Global EGFR-TKI Sales by Manufacturers (2021-2026)
  3. 3.3 Global EGFR-TKI Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global EGFR-TKI Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global EGFR-TKI Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global EGFR-TKI Manufacturers, Product Type & Application
  7. 3.7 Global EGFR-TKI Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global EGFR-TKI Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 EGFR-TKI Players Market Share by Revenue in 2025
  11. 3.8.3 2025 EGFR-TKI Tier 1, Tier 2, and Tier 3
4 EGFR-TKI Market by Type
  1. 4.1 EGFR-TKI Type Introduction
  2. 4.1.1 Afatinib
  3. 4.1.2 Aumolertinib
  4. 4.1.3 Icotinib
  5. 4.1.4 Osimertinib
  6. 4.1.5 Dacomitinib
  7. 4.1.6 Erlotinib
  8. 4.1.7 Furmonertinib
  9. 4.1.8 Gefitinib
  10. 4.1.9 Lazertinib
  11. 4.1.10 Other
  12. 4.2 Global EGFR-TKI Sales by Type
  13. 4.2.1 Global EGFR-TKI Sales by Type (2021 VS 2025 VS 2032)
  14. 4.2.2 Global EGFR-TKI Sales by Type (2021-2032)
  15. 4.2.3 Global EGFR-TKI Sales Market Share by Type (2021-2032)
  16. 4.3 Global EGFR-TKI Revenue by Type
  17. 4.3.1 Global EGFR-TKI Revenue by Type (2021 VS 2025 VS 2032)
  18. 4.3.2 Global EGFR-TKI Revenue by Type (2021-2032)
  19. 4.3.3 Global EGFR-TKI Revenue Market Share by Type (2021-2032)
5 EGFR-TKI Market by Application
  1. 5.1 EGFR-TKI Application Introduction
  2. 5.1.1 Segment by Application
  3. 5.1.2 Hospital and Clinic
  4. 5.1.3 Retail Pharmacies
  5. 5.1.4 Other
  6. 5.2 Global EGFR-TKI Sales by Application
  7. 5.2.1 Global EGFR-TKI Sales by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global EGFR-TKI Sales by Application (2021-2032)
  9. 5.2.3 Global EGFR-TKI Sales Market Share by Application (2021-2032)
  10. 5.3 Global EGFR-TKI Revenue by Application
  11. 5.3.1 Global EGFR-TKI Revenue by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global EGFR-TKI Revenue by Application (2021-2032)
  13. 5.3.3 Global EGFR-TKI Revenue Market Share by Application (2021-2032)
6 Global EGFR-TKI Sales by Region
  1. 6.1 Global EGFR-TKI Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global EGFR-TKI Sales by Region (2021-2032)
  3. 6.2.1 Global EGFR-TKI Sales by Region (2021-2026)
  4. 6.2.2 Global EGFR-TKI Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America EGFR-TKI Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America EGFR-TKI Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe EGFR-TKI Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe EGFR-TKI Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific EGFR-TKI Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific EGFR-TKI Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa EGFR-TKI Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa EGFR-TKI Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global EGFR-TKI Revenue by Region
  1. 7.1 Global EGFR-TKI Revenue by Region
  2. 7.1.1 Global EGFR-TKI Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global EGFR-TKI Revenue by Region (2021-2026)
  4. 7.1.3 Global EGFR-TKI Revenue by Region (2027-2032)
  5. 7.1.4 Global EGFR-TKI Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America EGFR-TKI Revenue (2021-2032)
  8. 7.2.2 North America EGFR-TKI Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe EGFR-TKI Revenue (2021-2032)
  11. 7.3.2 Europe EGFR-TKI Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific EGFR-TKI Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific EGFR-TKI Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa EGFR-TKI Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa EGFR-TKI Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 ArriVent Biopharma
  2. 8.1.1 ArriVent Biopharma Company Information
  3. 8.1.2 ArriVent Biopharma Business Overview
  4. 8.1.3 ArriVent Biopharma EGFR-TKI Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 ArriVent Biopharma EGFR-TKI Product Portfolio
  6. 8.1.5 ArriVent Biopharma Recent Developments
  7. 8.2 AstraZeneca
  8. 8.2.1 AstraZeneca Company Information
  9. 8.2.2 AstraZeneca Business Overview
  10. 8.2.3 AstraZeneca EGFR-TKI Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 AstraZeneca EGFR-TKI Product Portfolio
  12. 8.2.5 AstraZeneca Recent Developments
  13. 8.3 Beacon Pharma
  14. 8.3.1 Beacon Pharma Company Information
  15. 8.3.2 Beacon Pharma Business Overview
  16. 8.3.3 Beacon Pharma EGFR-TKI Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Beacon Pharma EGFR-TKI Product Portfolio
  18. 8.3.5 Beacon Pharma Recent Developments
  19. 8.4 Boehringer Ingelheim Pharmaceuticals
  20. 8.4.1 Boehringer Ingelheim Pharmaceuticals Company Information
  21. 8.4.2 Boehringer Ingelheim Pharmaceuticals Business Overview
  22. 8.4.3 Boehringer Ingelheim Pharmaceuticals EGFR-TKI Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Boehringer Ingelheim Pharmaceuticals EGFR-TKI Product Portfolio
  24. 8.4.5 Boehringer Ingelheim Pharmaceuticals Recent Developments
  25. 8.5 Cipla
  26. 8.5.1 Cipla Company Information
  27. 8.5.2 Cipla Business Overview
  28. 8.5.3 Cipla EGFR-TKI Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Cipla EGFR-TKI Product Portfolio
  30. 8.5.5 Cipla Recent Developments
  31. 8.6 Drug International
  32. 8.6.1 Drug International Company Information
  33. 8.6.2 Drug International Business Overview
  34. 8.6.3 Drug International EGFR-TKI Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Drug International EGFR-TKI Product Portfolio
  36. 8.6.5 Drug International Recent Developments
  37. 8.7 Glenmark Pharmaceuticals
  38. 8.7.1 Glenmark Pharmaceuticals Company Information
  39. 8.7.2 Glenmark Pharmaceuticals Business Overview
  40. 8.7.3 Glenmark Pharmaceuticals EGFR-TKI Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Glenmark Pharmaceuticals EGFR-TKI Product Portfolio
  42. 8.7.5 Glenmark Pharmaceuticals Recent Developments
  43. 8.8 Hanmi Pharmaceutical
  44. 8.8.1 Hanmi Pharmaceutical Company Information
  45. 8.8.2 Hanmi Pharmaceutical Business Overview
  46. 8.8.3 Hanmi Pharmaceutical EGFR-TKI Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Hanmi Pharmaceutical EGFR-TKI Product Portfolio
  48. 8.8.5 Hanmi Pharmaceutical Recent Developments
  49. 8.9 Johnson & Johnson
  50. 8.9.1 Johnson & Johnson Company Information
  51. 8.9.2 Johnson & Johnson Business Overview
  52. 8.9.3 Johnson & Johnson EGFR-TKI Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Johnson & Johnson EGFR-TKI Product Portfolio
  54. 8.9.5 Johnson & Johnson Recent Developments
  55. 8.10 Mylan
  56. 8.10.1 Mylan Company Information
  57. 8.10.2 Mylan Business Overview
  58. 8.10.3 Mylan EGFR-TKI Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Mylan EGFR-TKI Product Portfolio
  60. 8.10.5 Mylan Recent Developments
  61. 8.11 Pfizer
  62. 8.11.1 Pfizer Company Information
  63. 8.11.2 Pfizer Business Overview
  64. 8.11.3 Pfizer EGFR-TKI Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Pfizer EGFR-TKI Product Portfolio
  66. 8.11.5 Pfizer Recent Developments
  67. 8.12 Roche
  68. 8.12.1 Roche Company Information
  69. 8.12.2 Roche Business Overview
  70. 8.12.3 Roche EGFR-TKI Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Roche EGFR-TKI Product Portfolio
  72. 8.12.5 Roche Recent Developments
  73. 8.13 Teva
  74. 8.13.1 Teva Company Information
  75. 8.13.2 Teva Business Overview
  76. 8.13.3 Teva EGFR-TKI Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Teva EGFR-TKI Product Portfolio
  78. 8.13.5 Teva Recent Developments
  79. 8.14 Yuhan Corporation
  80. 8.14.1 Yuhan Corporation Company Information
  81. 8.14.2 Yuhan Corporation Business Overview
  82. 8.14.3 Yuhan Corporation EGFR-TKI Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Yuhan Corporation EGFR-TKI Product Portfolio
  84. 8.14.5 Yuhan Corporation Recent Developments
  85. 8.15 Betta Pharma
  86. 8.15.1 Betta Pharma Company Information
  87. 8.15.2 Betta Pharma Business Overview
  88. 8.15.3 Betta Pharma EGFR-TKI Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Betta Pharma EGFR-TKI Product Portfolio
  90. 8.15.5 Betta Pharma Recent Developments
  91. 8.16 Chengdu Brilliant Pharmaceuticals
  92. 8.16.1 Chengdu Brilliant Pharmaceuticals Company Information
  93. 8.16.2 Chengdu Brilliant Pharmaceuticals Business Overview
  94. 8.16.3 Chengdu Brilliant Pharmaceuticals EGFR-TKI Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Chengdu Brilliant Pharmaceuticals EGFR-TKI Product Portfolio
  96. 8.16.5 Chengdu Brilliant Pharmaceuticals Recent Developments
  97. 8.17 Hansoh Pharma
  98. 8.17.1 Hansoh Pharma Company Information
  99. 8.17.2 Hansoh Pharma Business Overview
  100. 8.17.3 Hansoh Pharma EGFR-TKI Sales, Price, Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Hansoh Pharma EGFR-TKI Product Portfolio
  102. 8.17.5 Hansoh Pharma Recent Developments
  103. 8.18 Shanghai Allist Pharmaceuticals
  104. 8.18.1 Shanghai Allist Pharmaceuticals Company Information
  105. 8.18.2 Shanghai Allist Pharmaceuticals Business Overview
  106. 8.18.3 Shanghai Allist Pharmaceuticals EGFR-TKI Sales, Price, Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Shanghai Allist Pharmaceuticals EGFR-TKI Product Portfolio
  108. 8.18.5 Shanghai Allist Pharmaceuticals Recent Developments
  109. 8.19 Wanbang Biopharmaceuticals
  110. 8.19.1 Wanbang Biopharmaceuticals Company Information
  111. 8.19.2 Wanbang Biopharmaceuticals Business Overview
  112. 8.19.3 Wanbang Biopharmaceuticals EGFR-TKI Sales, Price, Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Wanbang Biopharmaceuticals EGFR-TKI Product Portfolio
  114. 8.19.5 Wanbang Biopharmaceuticals Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 EGFR-TKI Value Chain Analysis
  2. 9.1.1 EGFR-TKI Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 EGFR-TKI Production Mode & Process
  6. 9.2 EGFR-TKI Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 EGFR-TKI Distributors
  9. 9.2.3 EGFR-TKI Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst